|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 218.66 USD | -0.41% |
|
+6.98% | +5.66% |
| 01-17 | H&F weighs $9 billion-plus sale of medical device maker Cordis, Bloomberg News reports | RE |
| 01-17 | Wall Street ends little changed before long weekend | RE |
| Capitalization | 527B 454B 423B 394B 733B 47,800B 788B 4,863B 1,918B 22,800B 1,976B 1,935B 83,255B | P/E ratio 2025 * |
21.3x | P/E ratio 2026 * | 22.6x |
|---|---|---|---|---|---|
| Enterprise value | 552B 476B 443B 413B 768B 50,104B 827B 5,098B 2,010B 23,900B 2,071B 2,028B 87,269B | EV / Sales 2025 * |
5.89x | EV / Sales 2026 * | 5.52x |
| Free-Float |
77.08% | Yield 2025 * |
2.36% | Yield 2026 * | 2.44% |
Last Transcript: Johnson & Johnson
| 1 day | -0.41% | ||
| 1 week | +6.98% | ||
| Current month | +5.66% | ||
| 1 month | +3.96% | ||
| 3 months | +13.17% | ||
| 6 months | +34.16% | ||
| Current year | +5.66% |
| 1 week | 203.85 |  | 220.11 |
| 1 month | 200.91 | | 220.11 |
| Current year | 200.91 | | 220.11 |
| 1 year | 141.5 | | 220.11 |
| 3 years | 140.68 | | 220.11 |
| 5 years | 140.68 | | 220.11 |
| 10 years | 94.28 | | 220.11 |
| Manager | Title | Age | Since |
|---|---|---|---|
Joaquin Duato
CEO | Chief Executive Officer | 63 | 03/01/2022 |
Joseph Wolk
DFI | Director of Finance/CFO | 59 | 01/07/2018 |
Penny M. Heaton
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/08/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Anne Mulcahy
BRD | Director/Board Member | 72 | 23/10/2009 |
Mark McClellan
BRD | Director/Board Member | 62 | 15/10/2013 |
Mary Beckerle
BRD | Director/Board Member | 71 | 09/06/2015 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -4.10% | 14.01% | 303 M€ | |
| +1.50% | 12.91% | 26 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.41% | +6.98% | +48.72% | +26.86% | 527B | |
| +0.53% | -2.37% | +43.09% | +190.27% | 930B | |
| -0.31% | -2.60% | +24.94% | +40.25% | 379B | |
| +0.93% | +2.38% | +31.46% | +18.47% | 371B | |
| +0.19% | -1.15% | +28.47% | +21.14% | 292B | |
| +0.98% | +1.37% | +29.42% | +35.03% | 276B | |
| -1.93% | -1.54% | +11.14% | -1.47% | 270B | |
| +6.49% | +1.95% | -32.44% | -18.44% | 268B | |
| +0.12% | +1.32% | +21.43% | +22.64% | 178B | |
| +3.01% | +3.15% | +36.01% | +46.25% | 155B | |
| Average | +0.96% | +0.95% | +24.22% | +38.10% | 364.59B | |
| Weighted average by Cap. | +0.70% | +0.62% | +29.34% | +64.42% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 93.76B 80.83B 75.25B 70.05B 130B 8,507B 140B 866B 341B 4,058B 352B 344B 14,817B | 98.77B 85.15B 79.26B 73.79B 137B 8,961B 148B 912B 360B 4,275B 370B 363B 15,608B |
| Net income | 23.5B 20.26B 18.86B 17.56B 32.69B 2,132B 35.17B 217B 85.54B 1,017B 88.12B 86.31B 3,713B | 23.03B 19.85B 18.48B 17.21B 32.04B 2,090B 34.47B 213B 83.83B 997B 86.36B 84.58B 3,639B |
| Net Debt | 25.4B 21.9B 20.38B 18.98B 35.33B 2,305B 38.02B 234B 92.46B 1,099B 95.25B 93.29B 4,014B | 18.82B 16.22B 15.1B 14.06B 26.18B 1,707B 28.17B 174B 68.5B 814B 70.57B 69.12B 2,974B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/01/26 | 218.66 $ | -0.41% | 10,021,515 |
| 15/01/26 | 219.57 $ | +0.47% | 8,492,116 |
| 14/01/26 | 218.55 $ | +2.29% | 11,858,784 |
| 13/01/26 | 213.65 $ | +1.87% | 11,379,590 |
| 12/01/26 | 209.72 $ | +2.61% | 11,794,339 |
Delayed Quote Nyse, January 17, 2026 at 12:00 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- JNJ Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition